BiotechTube

0.5 ml dose of 1.1 mcg VAX-24 + 0.5 ml dose of PCV20 + 0.5 ml dose of 2.2 mcg VAX-24 + 0.5 ml dose of 2.2/4.4 mcg VAX-24

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pneumococcal Vaccines

Conditions

Pneumococcal Vaccines

Trial Timeline

Mar 29, 2023 → Aug 25, 2025

NCT ID
NCT05844423

About 0.5 ml dose of 1.1 mcg VAX-24 + 0.5 ml dose of PCV20 + 0.5 ml dose of 2.2 mcg VAX-24 + 0.5 ml dose of 2.2/4.4 mcg VAX-24

0.5 ml dose of 1.1 mcg VAX-24 + 0.5 ml dose of PCV20 + 0.5 ml dose of 2.2 mcg VAX-24 + 0.5 ml dose of 2.2/4.4 mcg VAX-24 is a phase 2 stage product being developed by VaxCyte for Pneumococcal Vaccines. The current trial status is completed. This product is registered under clinical trial identifier NCT05844423. Target conditions include Pneumococcal Vaccines.

What happened to similar drugs?

15 of 20 similar drugs in Pneumococcal Vaccines were approved

Approved (15) Terminated (1) Active (5)
✅PNEUMOVAX™ 23MerckApproved
✅Simultaneous administration of Pneumovax NP® and Fluvic HA syringe® + Sequential administration of Pneumovax NP® and Fluvic HA syringe®MerckApproved
✅21-valent pneumococcal conjugate vaccineMerckApproved
✅ProDiax-23 (PPSV23)MerckApproved
✅13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccinePfizerApproved
✅pneumococcus conjugate vaccine 7 valent to reduce carriagePfizerApproved
✅pneumococcus conjugate vaccinePfizerApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05844423Phase 2Completed

Competing Products

20 competing products in Pneumococcal Vaccines

See all competitors
ProductCompanyStageHype Score
V116 + PPSV23MerckPhase 3
40
V114 + QIV + Matching Placebo for V114MerckPhase 3
40
V114 + Prevnar 13™ + PNEUMOVAX™23MerckPhase 3
40
V114 Lot 1 + V114 Lot 2 + Prevnar 13™MerckPhase 2
35
PNEUMOVAX™ 23MerckApproved
43
Pneumococcal Vaccine, Polyvalent (23-valent)MerckPhase 3
40
V114 + Prevnar 13™ + PNEUMOVAX™23MerckPhase 3
40
V114 + Prevnar 13®MerckPhase 3
40
V114 Medium Dose + V114 High Dose + V114 Medium Dose with Alternative Carrier Protein + V114 High Dose with Alternative Carrier Protein + Prevnar 13™MerckPhase 1/2
32
V116 + PPSV23MerckPhase 3
40
V114MerckPhase 3
40
Prevnar 13™ + V114 + RotaTeq™ + Pentacel™ + RECOMBIVAX HB™ + HIBERIX™ + M-M-R™ II + VARIVAX™MerckPhase 3
40
V114 + Prevnar 13®MerckPhase 3
40
Pneumococcal Conjugate Vaccine (V114) + PNEUMOVAX® 23 + PREVNAR 13®MerckPhase 2
35
V114-A + V114-B + Prevnar 13®MerckPhase 2
35
V116 + Pneumovax™23MerckPhase 1/2
32
V114 + Prevnar 13™MerckPhase 3
40
V114 + Prevnar 13™MerckPhase 2
35
Simultaneous administration of Pneumovax NP® and Fluvic HA syringe® + Sequential administration of Pneumovax NP® and Fluvic HA syringe®MerckApproved
43
21-valent pneumococcal conjugate vaccineMerckApproved
50